Stock Events

TheraCryf 

GBX0.74
5
+GBX0+0% Thursday 10:43

Statistics

Day High
0.74
Day Low
0.74
52W High
2.1
52W Low
0.59
Volume
50,000
Avg. Volume
774,564
Mkt Cap
3.21M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

4
DEC
Earnings
 

Earnings

4DecExpected
Q1 2024
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TCF.LSE. It's not an investment recommendation.
Alphabet
77346
GOOGL
Apple
67415
AAPL
Microsoft
62824
MSFT
Amazon
58558
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Astrazeneca
AZN.LSE
Mkt Cap181.97B
GSK
GSK.LSE
Mkt Cap59.53B
Bristol-Myers Squibb
BMY
Mkt Cap101.27B
Bristol Myers Squibb is a global biopharmaceutical company with a strong portfolio in cancer and immune disorder treatments, competing in the same space as Evgen Pharma.
Pfizer
PFE
Mkt Cap164.39B
Pfizer is involved in the discovery, development, and manufacture of healthcare products including medicines and vaccines for oncology, making it a competitor.
Merck
MRK
Mkt Cap300.25B
Merck & Co., Inc. focuses on cancer, among other areas, with a strong emphasis on innovative treatments that could compete with Evgen Pharma's offerings.
Novartis
NVS
Mkt Cap244.75B
Novartis AG operates globally in areas including oncology and neurology, directly competing with Evgen Pharma's research and development focus.
Roche
RHHBY
Mkt Cap272.83B
Roche Holding AG specializes in pharmaceuticals and diagnostics in oncology and other fields, positioning it as a competitor to Evgen Pharma.
Sanofi
SNY
Mkt Cap141.43B
Sanofi focuses on healthcare solutions in areas like oncology, which could see it competing with Evgen Pharma for market share in similar therapeutic areas.
Abbvie
ABBV
Mkt Cap346.75B
AbbVie is a research-based biopharmaceutical company with a strong emphasis on oncology, making it a competitor to Evgen Pharma.
AMGEN
AMGN
Mkt Cap179.38B
Amgen focuses on human therapeutics, including oncology and neuroscience, areas that are of interest to Evgen Pharma, making them competitors.

About

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and glioblastoma, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
Show more...
CEO
Dr. Huw Jones BSc, Ph.D.
Employees
9
Country
GB
ISIN
GB00BSVYN304

Listings

LSE
GB
TCF.LSE
F
DE
8EV.F